Ohr
Pharmaceutical Inc. (Nasdaq: OHRP) reported positive results from a Phase II
clinical trial of its retinal vein occlusion treatment OHR-102. The stock price leaped 92 cents to $3.19.
Ohr reports positive trial results
July 13, 2015 at 12:51 PM EDT
